Abstract:There has been over half a century since the discovery of hepatitis B virus (HBV) to now, but approximately 300 million patients with chronic hepatitis B (CHB) still live in the world, resulting in about one million deaths every year. Although currently approved antivirals (e.g., nucleoside analogues) are effective at reducing HBV replication, they have almost no impact on the existing HBV covalently closed circular DNA (cccDNA) reservoir. HBV cccDNA is a critical obstacle to the complete elimination of the virus via antiviral therapy. The true cure of HBV infection requires the eradication of viral cccDNA from HBV-infected cells; thus, the development of new agents directly or indirectly targeting HBV cccDNA is urgently needed due to the limitations of current available drugs against HBV infection. In this regard, it is the major focus of current anti-HBV research worldwide via different mechanisms to either inactivate/inhibit (functional cure) or eliminate (complete cure) HBV cccDNA. Therefore, this review discussed and summarized recent advances and challenges in efforts to inactivate/silence or eliminate viral cccDNA using anti-HBV agents from different sources, such as small molecules (including epigenetic drugs) and polypeptides/proteins, and siRNA or gene-editing approaches targeting/attenuating HBV cccDNA via different mechanisms, as well as future directions that may be considered in efforts to truly cure chronic HBV infection. In conclusion, no breakthrough has been made yet in attenuating HBV cccDNA, although a number of candidates have advanced into the phase of clinical trials. Furthermore, the overwhelming majority of the candidates function to indirectly target HBV cccDNA. No outstanding candidate directly targets HBV cccDNA. Relatively speaking, CCC_R08 and nitazoxanide may be some of the most promising agents to clear HBV infection in small molecule compounds. Additionally, CRISPR-Cas9 systems can directly target HBV cccDNA for decay and demonstrate significant anti-HBV activity. Consequently, gene-editing approaches targeting HBV cccDNA may be one of the most promising means to achieve the core goal of anti-HBV therapeutic strategies. In short, more basic studies on HBV infection need to be carried out to overcome these challenges.

Hepatitis B: New Approaches for Antiviral Chemotherapy

HBV life cycle and novel drug targets

Perspective on Emerging Therapies to Achieve Functional Cure of Chronic Hepatitis B

Current trends and advances in antiviral therapy for chronic hepatitis B

New advances in drug therapy of chronic hepatitis B infection

Novel mechanistic insights – A brand new Era for anti-HBV drugs

Novel Approaches Towards Conquering Hepatitis B Virus Infection

Novel therapeutic strategies for chronic hepatitis B

New Insights into Hepatitis B Virus Biology and Implications for Novel Antiviral Strategies

Developments in pharmacotherapeutic agents for hepatitis B - how close are we to a functional cure?

Current Status and Challenges in Anti-Hepatitis B Virus Agents Based on Inactivation/Inhibition or Elimination of Hepatitis B Virus Covalently Closed Circular DNA.

Advances in the Pharmacological Management of Chronic Hepatitis B

New anti-hepatitis B virus drugs under development and evaluation.

New Anti-Hepatitis B Virus Drugs under Development and Evaluation

Recent advance of the hepatitis B virus inhibitors: a medicinal chemistry overview

Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation

Emerging drugs for the treatment of hepatitis B

Emerging Antivirals for the Treatment of Hepatitis B

Antiviral Natural Products Against Chronic Hepatitis B: Recent Developments

Anti-Hbv Drugs: Progress, Unmet Needs, and New Hope

Advanced Therapeutics, Vaccinations, and Precision Medicine in the Treatment and Management of Chronic Hepatitis B Viral Infections; Where Are We and Where Are We Going?